Search Results

AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington.

AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, announced a technology transfer and license agreement with the University of Louisville, Kentucky.

AnaBios announced the inaugural Translational Research Conference to be held Feb. 27-28, 2023, in San Diego, California.

AnaBios Corporation announced an investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors.

AnaBios is pleased to announce the hire of Blake Anson, Ph.D., as Vice President of Business Development.

Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further improve the success of preclinical drug discovery research.

Today, AnaBios announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) to study adult human primary cardiomyocytes as a reference for cellular properties and drug-induced effects on cardiac function.

Poolbeg Pharma announces that it has acquired an exclusive licence from InsuCaps Limited, a sister company of AnaBio Technologies, to use InsuCaps’ patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome related diseases including obesity, pre-diabetes and diabetes.

AnaBios Corp. today announced it is providing validated human dorsal root ganglion (hDRG) to the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), for research collaborations to develop human cell-based screening platforms and novel drugs to treat pain and opioid use disorder.

The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).